Use of glucocorticoids in the management of immunotherapy‐related adverse effects

Use of glucocorticoids in the management of immunotherapy‐related adverse effects

Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy‐related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the...

Full description

Bibliographic Details
Main Authors: Hanping Wang, Jiaxin Zhou, Xiaoxiao Guo, Yue Li, Lian Duan, Xiaoyan SI, Li Zhang
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Thoracic Cancer
Subjects:
Glucocorticoids
glucocorticosteroids
immune checkpoint inhibitor
immune suppressors
immunotherapy‐related adverse effects
Online Access:https://doi.org/10.1111/1759-7714.13589

Internet

https://doi.org/10.1111/1759-7714.13589

Similar Items